

BUY

TP: Rs 11,510 | ▲ 15%

ULTRATECH CEMENT

Cement

30 April 2024

Strong growth; cost savings drive margins; maintain BUY

- Strong volume gains of ~11% YoY push revenue growth of 9% even though realisation falls by 3.5%
- Cost efficiencies (5% YoY fall) offset weak realisation; EBITDA margin climbs 300bps YoY to 20.3%, EBITDA/t to Rs 1,204 (+15% YoY)
- Maintain BUY rating with an unchanged TP of Rs 11,510 set at 16x FY26E EV/EBITDA (unchanged), earnings lowered marginally for FY25

Milind Raginwar

research@bobcaps.in

Strong volume push aids revenue gains in a challenging quarter: UTCEM reported 9% YoY (+23% QoQ) revenue growth to Rs 198bn in Q4FY24 backed by strong volume growth of 11% to 33.4mn tonnes on a high base. Capacity utilisation at ~98% was the highlight but typical in the busy Q4. Effectively, realisations adjusted to Rs60/t, incentives fell by 3.5%/6% YoY/QoQ at Rs 5,193/t.

Cost savings remain the highlight: Operating cost/tonne fell 5% YoY (-8% QoQ) in Q4 to Rs 4,729/t offsetting the realisations decline. This was aided by raw material, fuel and logistics cost efficiencies. Fuel cost (raw material adjusted) fell 10% YoY (-5% QoQ) to Rs 1,490/t, with blended fuel consumption cost staying flat YoY at US\$ 150/t. Logistics cost/t stayed flat YoY at Rs 1,374/t (+2% QoQ) while other expenses rose 18% YoY (2% QoQ) to ~Rs 22bn. Better operating leverage helped cost gains.

Cost savings lend margins push: EBITDA increased 28% YoY (+32% QoQ) to Rs 40.2bn and margins jumped 300bps YoY (+150bps QoQ) to 20.3%. Helped by cost savings, EBITDA/t climbed 15% YoY (+1 QoQ) to Rs 1,204/t.

Expansion on track: UTCEM's Phase-II and -III expansion of 24.4mt and 21.9 mt is on schedule, which will take capacity to 157.4mt by FY25 and further add 21.9mt by FY27 (clinker capacity addition expected at 10mt-12mt). Capex guidance for FY24 is now ~Rs 90bn. The capex will be ~Rs324bn spread over FY25/FY26/FY27. The capex guidance for FY25 is 95bn followed by Rs100bn/Rs110bn in FY26/FY27. The Kesoram Industries proposed transaction has received CCI approval. UTCEM plans to merge the KSI assets and is awaiting approval from SEBI and the stock exchanges, following which the scheme will be submitted to the NCLT.

Maintain BUY rating: We cut FY25 EBITDA/EPS estimates by ~3.5% amid elections/global uncertainties, while retaining our FY26 forecasts. Our FY23-FY26 EBITDA/PAT CAGR is baked in at 26%/32%. Given effective cost management, healthy growth and a strong balance sheet, we continue to value UTCEM at 16x FY26E EV/EBITDA to arrive at a TP of Rs 11,510 (unchanged) and maintain our BUY rating on the stock.

Key changes

Target	Rating
◀ ▶	◀ ▶

Ticker/Price	UTCEM IN/Rs 9,972
Market cap	US\$ 35.0bn
Free float	40%
3M ADV	US\$ 39.7mn
52wk high/low	Rs 10,526/Rs 7,434
Promoter/FPI/DII	60%/15%/17%


Source: NSE | Price as of 30 Apr 2024

Key financials

Y/E 31 Mar	FY24P	FY25E	FY26E
Total revenue (Rs mn)	6,86,406	7,66,364	8,91,821
EBITDA (Rs mn)	1,35,678	1,61,210	1,98,627
Adj. net profit (Rs mn)	69,769	88,708	1,13,360
Adj. EPS (Rs)	241.7	307.3	392.7
Consensus EPS (Rs)	241.7	305.0	381.0
Adj. ROAE (%)	12.4	14.1	15.8
Adj. P/E (x)	41.3	32.4	25.4
EV/EBITDA (x)	20.9	17.6	14.4
Adj. EPS growth (%)	41.9	27.1	27.8

Source: Company, Bloomberg, BOBCAPS Research | P – Provisional

Stock performance



Source: NSE



Fig 1 – Earnings call highlights

Parameter	Q4FY24	Q3FY24	Our view
Volumes and realisations	<p>Management indicated that Indian industry grew at ~ 9% in FY24 and 7-8% in 4QFY24. Demand may hover ~ 7-9% in FY25 after early moderation and will stay in higher single digits. UTCEM trade volume was 65% in 4QFY24 and premium product mix was 23.9% of the trade sales, higher by 17% YoY.</p> <p>All-India capacity utilisation increased by ~200 basis points to 71%. UTCEM achieved capacity utilisation of ~85% in FY24, thus consistently making inroads into the market.</p> <p>Moderation of cement prices was across regions in 4Q in addition to the decline in 3QFY24. However, in 1Q25, prices showed healthy revival except in North and West India (on a higher base).</p>	<p>Domestic volumes grew 5% YoY and utilisation stood at 77% in Q3FY24. The white cement and RMC segments grew 13% and 29% YoY respectively and overall trade volumes stood at 64%.</p> <p>Prices across India were a mixed bag, effectively staying flat YoY in 3QFY24.</p>	<p>FY25 demand is likely to be back-ended due to elections and monsoon quarter in the 1H. Effectively, pricing softness may continue for the short term.</p> <p>Higher capacity utilisation is typical in the busy 4Q.</p>
Margins	<p>Management expects overall cost savings of Rs 100-300 per tonne in the next 1-3 years. Fuel cost is expected to moderate further post 3QFY25 after utilising full high-cost inventory. Fuel cost during 4QFY24 was ~2.03/kcal (vs ~2.048/kcal /kcal in Q3FY24). Blended cost of fuel consumed in 4QFY24 was \$150/t flat vs 3QFY24 and UTCEM is expected to reach ~ \$130/t by 4QFY25.</p>	<p>Per tonne raw material cost rose 5.6% YoY (+2.3% QoQ) while logistics cost dipped 1.3% YoY (+1.6% QoQ) during Q3FY24. Fuel cost stood at Rs 2.05/kcal, pet coke price was at US\$ 126/t and blended fuel consumption cost stood at US\$ 130/t. Management expects fuel cost to reduce further by 7-8% in 4QFY24.</p>	<p>Management has guided for cost savings of Rs 100-300 per tonne incrementally, contributed by better clinker conversion ratio, higher usage of green energy and logistic cost savings. Any better-than-expected cost savings will add to higher EBITDA/t.</p>
Capacity	<p>The 21.9mtpa Phase III plan is expected to be completed by FY27. Phase II & III are on track and there is no change in the schedule.</p> <p>The organic expansions plans are on track. The Kesoram Industries-proposed transaction has received Competition Commission of India (CCI) approval. UTCEM plans to merge the KSI assets and is awaiting approval from the Securities Exchange Board of India and stock exchanges, following which the scheme will be submitted to the National Company Law Tribunal.</p> <p>Effectively, the Hotgi grinding unit expansion in Maharashtra is currently on hold.</p>	<p>Management indicated that its Phase II capacity expansion of 24.4mt is on schedule.</p> <p>Phase III expansion of 21.9mt by FY27 was announced in Q3FY24. Clinker capacity addition in this phase is expected at 10m-12mt.</p> <p>Total capacity will rise to 179.3mt by FY27 post Phase III including organic and inorganic addition.</p>	<p>Capacity expansion plans are on schedule. The Phase III plan suggests that capacity/volume market share will be maintained till FY28-FY29. Additionally, KSI assets will help make further inroads into the southern states of Telangana and Karnataka.</p>

Parameter	Q4FY24	Q3FY24	Our view
Capex	<p>The capex will be ~Rs 324bn, spread over FY25/FY26/FY27. The capex guidance for FY25 is Rs 95bn followed by Rs 100bn/Rs 110bn in FY26 and FY27 each.</p> <p>This includes the outlay for inorganic growth following the acquisition of Kesoram Industries' cement assets.</p>	<p>Capex guidance for FY24 has exceeded the initial plan and now stands at ~Rs 90bn, with a similar sum guided for FY25. Capex apportioned for Phase III expansion is ~Rs 60bn (excluding maintenance capex of Rs 10bn-20bn). This includes the outlay for inorganic growth following the acquisition of Kesoram Industries' cement assets</p>	<p>Despite aggressive capital expenditure plans, healthy cash flows and sharp focus on maintaining balance sheet health has been sustained.</p>
Green energy	<p>Cumulatively the percentage share in total energy consumption will be ~60% in FY27 from the current 24% in FY24. The cost of green power and WHRS is almost 90% lower than thermal power and renewable energy would be 40% lower than thermal energy. WHRS capacity will be enhanced to 150MW in one year.</p>	<p>Green energy formed 24% of UTCEM's total power consumption in Q3FY24. Management expects this share to double by FY25 with a target to reach 60% by FY27 (of which solar energy share is targeted at ~34% and WHRS share at ~26%).</p>	<p>No major change in the guidance on use of alternate energy sources. Effectively, the spikes in conventional energy cost are likely to be muted following the shift towards alternate fuels.</p>
Other key points	<p>UTCEM targets zero net cash on the balance sheet by FY25-end. Including Kesoram's debt of Rs 27bn UTCEM will end up with Rs 15bn to Rs 20bn of net debt.</p> <p>Incentives amounts to Rs 60/t on the Q4 volume contributing ~ Rs2bn in the topline.</p>	<p>UTCEM acquired Kesoram's cement business during Q3FY24 and expects the merger to become effective from 1 Apr 2024.</p> <p>Other expenditure in Q3FY24 amounted to ~Rs 21.4bn which includes maintenance cost brought forward from Q4FY24.</p> <p>Incentives for incremental capacity additions are available in the states of Rajasthan, Bihar and Uttar Pradesh.</p>	<p>UTCEM's balance sheet is expected to remain strong and strengthen further in the next couple of years aided by healthy contributions from new organic and inorganic business units.</p> <p>Incentives for incremental capacity additions are available in the states of Rajasthan, Bihar and Uttar Pradesh.</p>

Source: Company, BOBCAPS Research | RMC: Ready Mix Concrete, WHRS: Waste Heat Recovery System, AFR: Alternate Fuel & Raw Material

Fig 2 – Key quarterly metrics

Parameter	Q4FY24	Q4FY23	YoY %	Q3FY24	QoQ %
Volumes (mn mt)	33.4	30.1	10.9	25.6	30.5
Cement realisations (Rs/mt)	5,193	5,382	(3.5)	5,517	(5.9)
Operating costs (Rs/mt)*	4,729	4,977	(5.0)	5,134	(7.9)
EBITDA/t (Rs)	1,204	1,044	15.4	1,188	1.3


Source: Company, BOBCAPS Research | *Aggregate cost

Fig 3 – Quarterly performance

(Rs mn)	Q4FY24	Q4FY23	YoY (%)	Q3FY24	QoQ (%)
Net Sales	1,98,059	1,81,210	9.3	1,61,735	22.5
Expenditure					
Change in stock	4,692	2,417	94.2	(2,307)	-
Raw material	26,631	24,502	8.7	22,628	17.7
Purchased products	4,848	7,986	(39.3)	8,592	(43.6)
Power & fuel	46,626	48,234	(3.3)	38,107	22.4
Freight	45,876	41,378	10.9	35,697	28.5
Employee costs	7,197	6,732	6.9	7,208	(0.1)
Other expenses	21,986	18,551	18.5	21,409	2.7
Total Operating Expenses	1,57,857	1,49,800	5.4	1,31,334	20.2
EBITDA	40,202	31,410	28.0	30,401	32.2
EBITDA margin (%)	20.3	17.3	296bps	18.8	150bps
Other Income	1,542	2,006	(23.1)	1,914	(19.4)
Interest	2,268	1,749	29.7	2,369	(4.3)
Depreciation	7,857	6,948	13.1	7,124	10.3
PBT	31,619	24,719	27.9	22,821	38.6
Non-recurring items	(720)	0	0.0	0	0.0
PBT (after non-recurring items)	30,899	24,719	25.0	22,821	35.4
Tax	8,380	8,216	2.0	5,856	43.1
Reported PAT	22,520	16,503	36.5	16,965	32.7
Adjusted PAT	23,240	16,503	40.8	16,965	37.0
NPM (%)	11.7	9.1	263bps	10.5	124bps
Adjusted EPS (Rs)	80.5	57.2	40.8	58.8	37.0


Source: Company, BOBCAPS Research

Fig 4 – Volume growth strong, driven by front-ended demand




Source: Company, BOBCAPS Research

Fig 5 – Realisation under pressure as focus shifts to volume




Source: Company, BOBCAPS Research

Fig 6 – EBITDA/tonne aided by focus on cost savings




Source: Company, BOBCAPS Research

Fig 7 – Cost savings to continue as guided by UTCEM




Source: Company, BOBCAPS Research

Fig 8 – Freight cost savings aided by strategic plant locations



Source: Company, BOBCAPS Research

Fig 9 – Energy cost savings boosted by softer fuel cost



Source: Company, BOBCAPS Research

Valuation methodology

UTCEM will maintain its capacity leadership in all the major markets despite competitive pressure following the aggressive capex plans through to FY27. This also puts the company on a strong growth path to retain volume market share too. Additionally, Rs 100-300 per tonne of cost savings guidance augurs well for providing a boost to the EBITDA/t on a higher volume base in the next two years. This helps to offer added levers to enhance realisations and margins even as it is positioned as a capacity leader. The acquisition of Kesoram Industries' cement assets will also consolidate its presence in the states of Telangana and Maharashtra.

However, factoring in short term concerns on demand following general elections/global uncertainties we cut our FY25 EBITDA/EPS estimates by ~3.5%, while retaining our FY26 forecasts. Our FY23-FY26 EBITDA/PAT CAGR is baked in at 26%/32%. Given effective cost management, healthy growth and a strong balance sheet, we continue to value UTCEM at 16x FY26E EV/EBITDA to arrive at a TP of Rs 11,510 (unchanged) and maintain our BUY rating on the stock. Despite aggressive capex, the balance sheet remains strong and is the key. At our TP, the stock trades at a replacement cost of Rs 212bn/mt, a premium of ~2.5x to the industry.

Fig 10 – Revised estimates

(Rs mn)	New		Old		Change (%)	
	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E
Revenue	7,66,364	8,91,821	7,49,381	8,81,430	2.3	1.2
EBITDA	1,61,210	1,98,627	1,67,224	1,98,673	(3.6)	(0.0)
Adj PAT	88,708	1,13,360	91,888	1,13,368	(3.5)	(0.0)
Adj EPS (Rs)	307.3	392.7	318.3	392.8	(3.4)	(0.0)

Source: BOBCAPS Research

Fig 11 – Key assumptions

Parameter	FY23	FY24P	FY25E	FY26E
Volumes (mt)	103.13	112.80	128.04	143.81
Realisations (Rs/t)	5,149	5,379	5,304	5,491
Operating costs (Rs/t)	4,984	5,023	4,807	4,764
EBITDA/t (Rs)	873	1,085	1,170	1,259

Source: Company, BOBCAPS Research

Fig 12 – Valuation summary

Business (Rs mn)	FY26E
Target EV/EBITDA (x)	16.4
EBITDA	1,98,627
Target EV	32,66,218
Total EV	32,66,218
Net debt	(-55,809)
Target market capitalisation	33,22,027
Target price (Rs/sh)	11,510
Weighted average shares (mn)	288.7


Source: BOBCAPS Research

Fig 13 – Peer comparison

Ticker	Rating	TP (Rs)	EV/EBITDA (x)			EV/tonne (US\$)			ROE (%)			ROCE (%)		
			FY24	FY25E	FY26E	FY24	FY25E	FY26E	FY24	FY25E	FY26E	FY24	FY25E	FY26E
UTCEM IN	BUY	11,510	20.9	17.6	14.4	228.8	226.7	192.8	12.5	14.1	15.8	14.4	17.6	19.7
ACC IN	HOLD	2,542	12.2	12.0	10.4	106	128	115	8.1	14.1	14.1	11.0	18.4	18.3
ACEM IN	HOLD	552	10.8	14.1	11.2	215	171	159	9.5	7.9	8.6	13.8	14.2	16.3


Source: BOBCAPS Research

Fig 14 – P/E 1Y fwd: Valuation premium will be backed by healthy earnings




Source: Company, Bloomberg, BOBCAPS Research

Fig 15 – EV/EBITDA 1Y fwd: Strong financials to support valuations




Source: Company, Bloomberg, BOBCAPS Research

Fig 16 – Replacement cost: Size and efficiencies command a reasonable premium



Source: Company, Bloomberg, BOBCAPS Research

Fig 17 – EV/t: UTCEM likely to continue to command a premium



Source: Company, Bloomberg, BOBCAPS Research

Key risks

Key downside risks to our estimates are:

- Delays in the implementation of capex plans can hamper growth.
- Increasing competitive intensity and capacity addition may have negative impacts on cement sector pricing and can be detrimental for the industry and UTCEM, though the impact on UTCEM could be relatively lower due to its leadership position.
- Energy cost spikes due to global uncertainties could dampen profitability.

Sector recommendation snapshot

Company	Ticker	Market Cap (US\$ bn)	Price (Rs)	Target (Rs)	Rating
ACC	ACC IN	5.8	2,532	2,542	HOLD
Ambuja Cements	ACEM IN	15.0	620	552	HOLD
Dalmia Bharat	DALBHARA IN	4.1	1,838	2,346	BUY
JK Cement	JKCE IN	3.8	4,000	4,121	HOLD
JK Lakshmi Cement	JKLC IN	1.1	796	637	SELL
Orient Cement	ORCMNT IN	0.6	221	168	SELL
Shree Cement	SRCM IN	10.7	24,445	27,836	HOLD
Star Cement	STRCEM IN	1.2	237	193	HOLD
The Ramco Cements	TRCL IN	2.3	795	728	SELL
Ultratech Cement	UTCEM IN	35.0	9,972	11,510	BUY

Source: BOBCAPS Research, NSE | Price as of 30 Apr 2024

Financials

Income Statement

Y/E 31 Mar (Rs mn)	FY22A	FY23A	FY24P	FY25E	FY26E
Total revenue	4,97,294	6,04,626	6,86,406	7,66,364	8,91,821
EBITDA	1,09,364	99,312	1,35,678	1,61,210	1,98,627
Depreciation	(24,568)	(26,192)	(30,274)	(34,815)	(36,382)
EBIT	90,915	80,014	1,02,548	1,35,488	1,72,683
Net interest inc./(exp.)	(7,983)	(7,550)	(8,668)	(10,111)	(9,832)
Other inc./(exp.)	6,118	6,894	(2,855)	9,094	10,438
Exceptional items	5,352	0	(720)	0	0
EBT	88,284	72,464	93,160	1,25,377	1,62,851
Income taxes	(17,618)	(23,295)	(24,111)	(36,669)	(49,491)
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	0	0	0	0	0
Reported net profit	70,666	49,169	69,049	88,708	1,13,360
Adjustments	5,352	0	(720)	0	0
Adjusted net profit	65,314	49,169	69,769	88,708	1,13,360

Balance Sheet

Y/E 31 Mar (Rs mn)	FY22A	FY23A	FY24P	FY25E	FY26E
Accounts payables	97,164	1,13,015	1,26,815	1,37,661	1,53,593
Other current liabilities	49,400	68,224	94,541	76,240	78,320
Provisions	8,175	7,779	8,878	9,393	9,946
Debt funds	1,06,874	1,01,440	80,873	70,226	1,11,957
Other liabilities	52,299	54,758	64,250	65,500	66,950
Equity capital	2,887	2,887	2,887	2,887	2,887
Reserves & surplus	4,89,820	5,26,482	5,88,065	6,65,967	7,67,169
Shareholders' fund	4,92,706	5,29,369	5,90,952	6,68,853	7,70,055
Total liab. and equities	8,06,617	8,74,584	9,66,309	10,27,873	11,90,820
Cash and cash eq.	56,853	72,802	28,680	1,01,751	1,67,765
Accounts receivables	27,068	32,422	34,965	39,563	48,483
Inventories	51,625	60,842	80,358	90,244	1,07,460
Other current assets	1,05,963	1,03,368	83,962	1,15,283	1,26,811
Investments	63,074	72,602	71,397	71,397	71,397
Net fixed assets	4,30,850	4,69,216	4,55,902	4,92,874	5,61,912
CWIP	46,191	38,072	1,85,035	90,000	80,000
Intangible assets	24,993	25,260	26,010	26,760	26,991
Deferred tax assets, net	0	0	0	0	0
Other assets	0	0	0	0	0
Total assets	8,06,617	8,74,584	9,66,309	10,27,873	11,90,820

Cash Flows

Y/E 31 Mar (Rs mn)	FY22A	FY23A	FY24P	FY25E	FY26E
Cash flow from operations	58,914	99,263	1,47,378	72,028	1,32,093
Capital expenditures	(55,697)	(55,845)	(1,64,673)	22,497	(95,651)
Change in investments	58,463	(17,905)	42,860	(16,000)	(20,000)
Other investing cash flows	0	0	0	0	0
Cash flow from investing	2,766	(73,750)	(1,21,813)	6,497	(1,15,651)
Equities issued/Others	0	0	0	0	0
Debt raised/repaid	(66,361)	(5,434)	(20,567)	(10,647)	41,730
Interest expenses	7	8	9	10	10
Dividends paid	(10,670)	(10,927)	(10,807)	(10,807)	(12,158)
Other financing cash flows	(816)	(1,579)	3,342	0	0
Cash flow from financing	(77,848)	(17,940)	(28,032)	(21,454)	29,572
Chg in cash & cash eq.	(16,167)	7,573	(2,466)	57,071	46,014
Closing cash & cash eq.	56,853	72,803	28,681	1,01,751	1,67,765

Per Share

Y/E 31 Mar (Rs)	FY22A	FY23A	FY24P	FY25E	FY26E
Reported EPS	244.8	170.3	239.2	307.3	392.7
Adjusted EPS	226.3	170.3	241.7	307.3	392.7
Dividend per share	37.0	37.9	32.0	32.0	36.0
Book value per share	1,706.9	1,833.9	2,047.3	2,317.2	2,667.8

Valuations Ratios

Y/E 31 Mar (x)	FY22A	FY23A	FY24P	FY25E	FY26E
EV/Sales	5.6	4.7	4.1	3.7	3.2
EV/EBITDA	25.6	28.6	20.9	17.6	14.4
Adjusted P/E	44.1	58.5	41.3	32.4	25.4
P/BV	5.8	5.4	4.9	4.3	3.7

DuPont Analysis

Y/E 31 Mar (%)	FY22A	FY23A	FY24P	FY25E	FY26E
Tax burden (Net profit/PBT)	80.0	67.9	74.1	70.8	69.6
Interest burden (PBT/EBIT)	91.2	90.6	91.5	92.5	94.3
EBIT margin (EBIT/Revenue)	18.3	13.2	14.9	17.7	19.4
Asset turnover (Rev./Avg TA)	61.7	71.9	74.6	76.9	80.4
Leverage (Avg TA/Avg Equity)	1.7	1.6	1.6	1.6	1.5
Adjusted ROAE	14.3	9.6	12.4	14.1	15.8

Ratio Analysis

Y/E 31 Mar	FY22A	FY23A	FY24P	FY25E	FY26E
YoY growth (%)					
Revenue	16.5	21.6	13.5	11.6	16.4
EBITDA	(0.3)	(9.2)	36.6	18.8	23.2
Adjusted EPS	18.6	(24.7)	41.9	27.1	27.8
Profitability & Return ratios (%)					
EBITDA margin	21.6	16.2	19.5	20.8	22.0
EBIT margin	18.3	13.2	14.9	17.7	19.4
Adjusted profit margin	13.1	8.1	10.2	11.6	12.7
Adjusted ROAE	14.3	9.6	12.4	14.1	15.8
ROCE	13.9	12.0	14.4	17.6	19.7
Working capital days (days)					
Receivables	20	20	19	19	20
Inventory	38	37	43	43	44
Payables	89	80	83	82	80
Ratios (x)					
Gross asset turnover	0.9	1.0	1.1	1.1	1.1
Current ratio	1.6	1.4	1.0	1.6	1.9
Net interest coverage ratio	11.4	10.6	11.8	13.4	17.6
Adjusted debt/equity	0.2	0.2	0.1	0.1	0.1

Source: Company, BOBCAPS Research | Note: TA = Total Assets

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (“US”) OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**
 Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**
 SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025**
 Brand Name: **BOBCAPS**
 Trade Name: **www.barodaetrade.com**
 CIN: **U65999MH1996GOI098009**



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.
 Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%


HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): ULTRATECH CEMENT (UTCEM IN)



B – Buy, H – Hold, S – Sell, A – Add, R – Reduce

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS’s prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS’s associates may have financial interest in the subject company. BOBCAPS’s associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an “as is” basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS’s judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the “Losses”) which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom (“UK”):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd (“MSL”) who is authorised and regulated by the Financial Conduct Authority (“FCA”) in the United Kingdom (MSL and its affiliates are collectively referred to as “MAYBANK”). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK’s legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the “Order”), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as “relevant persons”).

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.